(Q44089913)

29 November 2017

title

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia (English)

1 reference

29 November 2017

1 reference

9

Hagop M Kantarjian

1 reference

29 November 2017

5

Alessandra Ferrajoli

1 reference

29 November 2017

4

William G Wierda

1 reference

29 November 2017

10

Susan O'Brien

1 reference

29 November 2017

8

Michael Andreeff

1 reference

29 November 2017

2

Michael J Keating

1 reference

29 November 2017

6

Susan Lerner

1 reference

Apostolia Maria Tsimberidou

29 November 2017

series ordinal

1

object named as

Apostolia M Tsimberidou

1 reference

29 November 2017

3

Francis J Giles

1 reference

29 November 2017

Miloslav Beran

7

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

29 November 2017

1 reference

29 November 2017

volume

100

1 reference

29 November 2017

issue

12

1 reference

29 November 2017

page(s)

2583-2591

1 reference

Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Treatment of advanced chronic lymphocytic leukemia by fludarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Second cancers in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Second cancers in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20264

7 January 2021

Identifiers

DOI

10.1002/CNCR.20264

1 reference

release_7n2m62smpnbg7lst2syo5zpkxa

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7n2m62smpnbg7lst2syo5zpkxa

24 November 2022

mapped directly with Wikidata item

1 reference